About HATIP

A regular electronic newsletter for health care workers and community-based organisations on HIV treatment in resource-limited settings.

Its publication is supported by the UK government's Department for International Development (DfID), the Diana, Princess of Wales Memorial Fund and the Stop TB Department of the World Health Organization.

Other supporters include Positive Action GlaxoSmithKline (founding sponsor); Abbott Fund; Abbott Molecular; Cavidi; Elton John AIDS Foundation; Merck & Co., Inc.; Pfizer Ltd; F Hoffmann La Roche; Schering Plough; and Tibotec, a division of Janssen Cilag.

latest aidsmap news

• Cluster of multi-drug resistant HIV transmissions in Seattle
• Hypersensitivity testing for abacavir slightly more cost-effective than tenofovir use, if both drugs equally potent
• HIV no longer bar to granting of US visa for short visits
• Kidney disease risk increased for patients with HIV and hepatitis C
• Nearly one in three UK HIV patients has considered suicide in the previous week
• A new day for health in South Africa: Manto is replaced as health minister by TAC supporter
• Fear and stigma creating hepatitis C transmission risk for HIV-positive gay men
• Imported malaria often severe among people with HIV
• Ezetimibe safe and effective for cholesterol reduction in patients taking HIV treatment
• Three million injecting drug users are HIV-positive